In Brief: Kremer LASIK PMA
This article was originally published in The Gray Sheet
Kremer LASIK PMA: Ophthalmologist and inventor Fredric Kremer's premarket approval application for single-site use of an excimer laser to perform Laser-K LASIK (laser in situ keratomileusis) procedures is scheduled for review by FDA's Ophthalmic Devices Panel on Feb. 13. Approval of the PMA, which encompasses treatment of myopia and myopic astigmatism at Kremer Laser Eye Center, in King of Prussia, Pennsylvania, would seal an agreement with LaserSight giving the company rights to the technology ("The Gray Sheet" Aug. 18, 1997, I&W-16). The Kremer PMA is not the first single-site LASIK PMA to go before the panel. In July 1997, the Ophthalmic panel unanimously recommended approval of a PMA from The Vision Correction Group, Atlanta ("The Gray Sheet" July 21, 1997, p. 10)...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.